Autosomal Dominant Polycystic Kidney Disease — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Chronic kidney disease detection using XceptionNet with Harmonic Addax Optimization.
Dedgaonkar Suruchi Gaurav et al. — Computational biology and chemistry (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41616602/
- 2.
GLIS3, a novel regulator of eicosanoid gene expression and metabolism in normal kidney and polycystic kidney disease.
Srivastava Chitrangda et al. — Biochemical pharmacology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41687831/
- 3.
KDIGO 2025 ADPKD guideline through pediatric eyes.
Van Reeth Olil E et al. — Pediatric nephrology (Berlin, Germany) (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41310108/
- 4.
Emodin retards renal cyst progression in ADPKD by inhibiting cell proliferation and decreasing oxidative stress.
Su Yuqi et al. — Life sciences (15 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41722769/
- 5.
ALDH1A1 is a potential novel target for treatment of ADPKD.
Zhang Liwen et al. — Kidney international (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41864666/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Recruiting — Phase 2 — AbbVie
https://clinicaltrials.gov/study/NCT06902558
- 2.
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
Recruiting — Phase 3 — The University of Queensland
https://clinicaltrials.gov/study/NCT04939935
- 3.
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
Recruiting — Phase 1 — PYC Therapeutics
https://clinicaltrials.gov/study/NCT06714006
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease, causing fluid-filled cysts to grow in the kidneys over decades and often leading to kidney failure. It affects approximately 25,000 Australians. The first disease-modifying treatment (tolvaptan) is now available, and research into additional therapies is progressing rapidly.
Most Recent Research
Chronic Kidney Disease (CKD) refers to a persistent and progressive impairment of kidney function occurring over a prolonged duration. Impaired kidney filtration can lead to the accumulation of waste products and excess fluid in the bloodstream, contributing to the development of secondary medical conditions. CKD leads to high blood pressure, glomerulonephritis, diabetes, and polycystic kidney disease. However, early detection of CKD is significant for decreasing complications and preventing kidney failure. However, generalization and class imbalance issues complicate the detection process. In order to improve CKD detection and resolve current limitations, an optimized deep learning approach is presented in this paper. This paper proposes a CKD detection framework that integrates XceptionNet with the Harmonic Addax Optimization Algorithm (HAOA). First, the chronic kidney dataset is provided as input and undergoes sigmoid normalization to ensure proper data scaling and structural consistency. Next, feature fusion is performed by a Deep Belief Network (DBN) with a Soergel metric. Then, data augmentation is performed utilizing the Synthetic Minority Overlapping Technique (SMOTE). At last, CKD detection is done using Xception with HAOA. Here, HAOA is developed by combining Harmonic analysis and the Addax Optimization Algorithm (AOA). The performance of the proposed Xception with the HAOA method is analyzed by the CKD dataset 1, CKD dataset 2, and the Risk Factor Prediction of CKD Dataset. It also achieves a good True Positive Rate (TPR) value of 94.679 %, True Negative Rate (TNR) of 92.777 %, and accuracy of 93.667 %, a precision of 92.258 %, and an F1-score of 93.453 %. The proposed model serves as an effective tool for early CKD diagnosis, reducing the risk of kidney failure and improving potential outcomes.
Common Questions
What is Autosomal Dominant Polycystic Kidney Disease?
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease, causing fluid-filled cysts to grow in the kidneys over decades and often leading to kidney failure. It affects approximately 25,000 Australians. The first disease-modifying treatment (tolvaptan) is now available, and research into additional therapies is progressing rapidly.
How many clinical trials are available for Autosomal Dominant Polycystic Kidney Disease?
RareWays currently indexes 165 clinical trials for Autosomal Dominant Polycystic Kidney Disease, of which 38 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Autosomal Dominant Polycystic Kidney Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Autosomal Dominant Polycystic Kidney Disease.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.